肝内胆管癌生物标志物:实现早期检测和个性化药物治疗

IF 2.3 3区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
Maurizio Capuozzo , Mariachiara Santorsola , Francesco Ferrara , Claudia Cinque , Stefania Farace , Renato Patrone , Vincenza Granata , Andrea Zovi , Guglielmo Nasti , Alessandro Ottaiano
{"title":"肝内胆管癌生物标志物:实现早期检测和个性化药物治疗","authors":"Maurizio Capuozzo ,&nbsp;Mariachiara Santorsola ,&nbsp;Francesco Ferrara ,&nbsp;Claudia Cinque ,&nbsp;Stefania Farace ,&nbsp;Renato Patrone ,&nbsp;Vincenza Granata ,&nbsp;Andrea Zovi ,&nbsp;Guglielmo Nasti ,&nbsp;Alessandro Ottaiano","doi":"10.1016/j.mcp.2024.101951","DOIUrl":null,"url":null,"abstract":"<div><p>Cholangiocarcinoma (CCA) is a rare malignancy originating from the biliary tree and is anatomically categorized as intrahepatic (iCCA), perihilar, and extrahepatic or distal. iCCA, the second most prevalent hepatobiliary cancer following hepatocellular carcinoma (HCC), constitutes 5–20 % of all liver malignancies, with an increasing incidence. The challenging nature of iCCA, combined with nonspecific symptoms, often leads to late diagnoses, resulting in unfavorable outcomes. The advanced phase of this neoplasm is difficult to treat with dismal results. Early diagnosis could significantly reduce mortality attributed to iCCA but remains an elusive goal. The identification of biomarkers specific to iCCA and their translation into clinical practice could facilitate diagnosis, monitor therapy response, and potentially reveal novel interventions and personalized medicine. In this review, we present the current landscape of biomarkers in each of these contexts. In addition to CA19.9, a widely recognized biomarker for iCCA, others such as A1BG, CYFRA 21–1, FAM19A5, MMP-7, RBAK, SSP411, TuM2-PK, WFA, <em>etc.</em>, as well as circulating tumor DNA, RNA, cells, and exosomes, are under investigation. Advancing our knowledge and monitoring of biomarkers may enable us to improve diagnosis, prognostication, and apply treatments dynamically and in a more personalized manner.</p></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":"73 ","pages":"Article 101951"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0890850824000033/pdfft?md5=34a9b1954e3ab966649bc816b4de14d2&pid=1-s2.0-S0890850824000033-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments\",\"authors\":\"Maurizio Capuozzo ,&nbsp;Mariachiara Santorsola ,&nbsp;Francesco Ferrara ,&nbsp;Claudia Cinque ,&nbsp;Stefania Farace ,&nbsp;Renato Patrone ,&nbsp;Vincenza Granata ,&nbsp;Andrea Zovi ,&nbsp;Guglielmo Nasti ,&nbsp;Alessandro Ottaiano\",\"doi\":\"10.1016/j.mcp.2024.101951\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cholangiocarcinoma (CCA) is a rare malignancy originating from the biliary tree and is anatomically categorized as intrahepatic (iCCA), perihilar, and extrahepatic or distal. iCCA, the second most prevalent hepatobiliary cancer following hepatocellular carcinoma (HCC), constitutes 5–20 % of all liver malignancies, with an increasing incidence. The challenging nature of iCCA, combined with nonspecific symptoms, often leads to late diagnoses, resulting in unfavorable outcomes. The advanced phase of this neoplasm is difficult to treat with dismal results. Early diagnosis could significantly reduce mortality attributed to iCCA but remains an elusive goal. The identification of biomarkers specific to iCCA and their translation into clinical practice could facilitate diagnosis, monitor therapy response, and potentially reveal novel interventions and personalized medicine. In this review, we present the current landscape of biomarkers in each of these contexts. In addition to CA19.9, a widely recognized biomarker for iCCA, others such as A1BG, CYFRA 21–1, FAM19A5, MMP-7, RBAK, SSP411, TuM2-PK, WFA, <em>etc.</em>, as well as circulating tumor DNA, RNA, cells, and exosomes, are under investigation. Advancing our knowledge and monitoring of biomarkers may enable us to improve diagnosis, prognostication, and apply treatments dynamically and in a more personalized manner.</p></div>\",\"PeriodicalId\":49799,\"journal\":{\"name\":\"Molecular and Cellular Probes\",\"volume\":\"73 \",\"pages\":\"Article 101951\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0890850824000033/pdfft?md5=34a9b1954e3ab966649bc816b4de14d2&pid=1-s2.0-S0890850824000033-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular and Cellular Probes\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0890850824000033\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890850824000033","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

胆管癌(CCA)是一种起源于胆管树的罕见恶性肿瘤,在解剖学上可分为肝内胆管癌(iCCA)、肝周胆管癌、肝外胆管癌或远端胆管癌。iCCA 是仅次于肝细胞癌(HCC)的第二大肝胆癌,占所有肝脏恶性肿瘤的 5-20%,且发病率呈上升趋势。iCCA 具有挑战性,再加上非特异性症状,往往导致诊断较晚,从而造成不良后果。这种肿瘤的晚期很难治疗,且效果不佳。早期诊断可大大降低 iCCA 的死亡率,但这仍是一个难以实现的目标。鉴定 iCCA 的特异性生物标志物并将其转化为临床实践,可促进诊断、监测治疗反应,并有可能揭示新型干预措施和个性化医疗。在这篇综述中,我们将介绍上述每种情况下生物标志物的现状。除了被广泛认可的 iCCA 生物标志物 CA19.9,其他生物标志物如 A1BG、CYFRA 21-1、FAM19A5、MMP-7、RBAK、SSP411、TuM2-PK、WFA 等,以及循环肿瘤 DNA、RNA、细胞和外泌体也在研究之中。我们对生物标志物的进一步了解和监测可帮助我们改进诊断和预后,并以更加个性化的方式动态应用治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments

Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments

Cholangiocarcinoma (CCA) is a rare malignancy originating from the biliary tree and is anatomically categorized as intrahepatic (iCCA), perihilar, and extrahepatic or distal. iCCA, the second most prevalent hepatobiliary cancer following hepatocellular carcinoma (HCC), constitutes 5–20 % of all liver malignancies, with an increasing incidence. The challenging nature of iCCA, combined with nonspecific symptoms, often leads to late diagnoses, resulting in unfavorable outcomes. The advanced phase of this neoplasm is difficult to treat with dismal results. Early diagnosis could significantly reduce mortality attributed to iCCA but remains an elusive goal. The identification of biomarkers specific to iCCA and their translation into clinical practice could facilitate diagnosis, monitor therapy response, and potentially reveal novel interventions and personalized medicine. In this review, we present the current landscape of biomarkers in each of these contexts. In addition to CA19.9, a widely recognized biomarker for iCCA, others such as A1BG, CYFRA 21–1, FAM19A5, MMP-7, RBAK, SSP411, TuM2-PK, WFA, etc., as well as circulating tumor DNA, RNA, cells, and exosomes, are under investigation. Advancing our knowledge and monitoring of biomarkers may enable us to improve diagnosis, prognostication, and apply treatments dynamically and in a more personalized manner.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular and Cellular Probes
Molecular and Cellular Probes 生物-生化研究方法
CiteScore
6.80
自引率
0.00%
发文量
52
审稿时长
16 days
期刊介绍: MCP - Advancing biology through–omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信